ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.188,34
-1,00%
S&P 500
5.214,08
0,51%
US Dollar vs BRL
5,1401
1,00%
Bitcoin
62.483,20
2,12%
Brent Oil
83,945
0,46%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. BiondVax Pharmaceuticals Ltd (BVXV)

  7. BiondVax Pharmaceuticals Ltd (BVXV) Notícias

BVXV

BiondVax Pharmaceuticals (BVXV)

BiondVax Pharmaceuticals Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BVXV
DataHoraFonteTítuloCódigoCompanhia
30/04/202417:06Edgar (US Regulatory)Form NT 20-F - Notification of inability to timely file Form 20-FNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/04/202418:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
10/04/202408:00PR Newswire (US)Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202417:17Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
12/03/202409:00PR Newswire (US)Scinai leadership to attend BIO-Europe Spring 2024NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
13/02/202409:00PR Newswire (US)Scinai Welcomes Liat Halpert as Head of Business Development and SalesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
04/01/202418:01PR Newswire (US)Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
20/11/202309:30PR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
07/09/202318:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/09/202307:00GlobeNewswire Inc.BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological TherapeuticsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202317:01Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
28/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202317:16Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
18/08/202311:07Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/08/202310:00GlobeNewswire Inc.BiondVax Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
01/08/202317:01GlobeNewswire Inc.Nasdaq Grants BiondVax Extension to Regain Compliance with Listing RulesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
11/07/202309:17GlobeNewswire Inc.IBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
08/06/202317:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
05/06/202308:00GlobeNewswire Inc.BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
15/05/202318:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
17/04/202317:52Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
17/04/202317:25GlobeNewswire Inc.BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business UpdateNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/04/202310:13Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
16/03/202314:10GlobeNewswire Inc.BiondVax to Present at BIO-Europe SpringNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
03/03/202316:07GlobeNewswire Inc.IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research InstitutesNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
02/02/202316:15GlobeNewswire Inc.BiondVax Presenting at BIO CEO & Investor ConferenceNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202311:45Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202310:17Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:BVXVBiondVax Pharmaceuticals Ltd
23/01/202308:25GlobeNewswire Inc.BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo StudyNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
06/01/202309:15GlobeNewswire Inc.BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo StudyNASDAQ:BVXVBiondVax Pharmaceuticals Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:BVXV

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
PDTC3
Padtec ON
BOV
OIBR3
OI ON
BOV
AZEV4
AZEVEDO PN
BOV
VVEO3
CM Hospitalar ON
BOV
PRIO3
PETRORIO ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
ENJU3
Enjoei ON
BOV
HBRE3
HBR Realty Empreendiment... ON
BOV
ENAT3
ENAUTA ON
BOV
JHSF3
JHSF PART ON
BOV
SGPS3
SPRINGS ON
BOV
MGLU3
MAGAZINE LUIZA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados